Retrospective Evaluation of the Randomized, Phase 3 MARQUEE Trial of Tivantinib (T) + Erlotinib (E) vs Placebo (P) + Erlotinib (E) Using VeriStrat in Patients With Previously Treated Non-Squamous NSCLC